Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On...( Blood clotting proteins factor 8 and ...),Health
Navigation Links
Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On Biologics
Date:2/24/2009
Blood clotting proteins factor 8 and 9 are first target indications
HOUSTON, Feb. 24 /PRNewswire-FirstCall/ -- Stem Cell Innovations' (Pink Sheets: SCLL) liver assist device program has additional application in the production of biosimilar and novel proteins. "Many of the commercially important therapeutic proteins are liver products and comprise a multibillion dollar market in the US," said James H. Kelly, CEO of SCLL. "Albumin, the clotting factors and alpha-1-antitrypsin are all produced naturally in the liver. Our C3A cell line produces each of these proteins at levels comparable to the natural liver cell. We already have the capability for large scale culture of the C3A cell line and expect that our PluriCell(TM) derived hepatocytes will have similar production capabilities. In addition, the C3A line provides an excellent host for the production of recombinant proteins due to the liver's massive synthetic capability."
In a sign that major pharmaceutical companies are becoming more aggressive about the biosimilar business, Merck is buying Insmed's portfolio of follow-on biologics for $130 million in cash. "We are exploring ways to fund our activities in this area through a spin out or an acquisition," said Kelly.
About Stem Cell Innovations, Inc.
SCLL is a cell biology company based in Houston, TX. The Company's ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations' proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy.
Additional information is available at www.stemcellinnovations.com and at www.activtox.com.
ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc.
'/>"/>
| SOURCE Stem Cell Innovations, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
2. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
3. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
4. Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend
5. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
6. Young Innovations, Inc. Provides Fourth Quarter Conference Call Details
7. Can payment and other innovations improve the quality and value of health care?
8. Stem Cell Innovations, Inc., Files New Patent Application Regarding Pluripotent Stem Cell Production
9. HC Innovations Expands Management Team, Adding Vice President of Human Resources
10. Pharos Innovations Strengthens Leadership Team, Informatics Program
11. Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008
Post Your Comments:
(Date:12/1/2009)... Encourages Older Persons and Healthcare Workers t... Upon Authority Data ,, HARRISBURG, Pa., Dec....l vaccine preventable deaths occur in those 65 and...rding to highlighted studies in the Pennsylvania P...afety Advisory . ,, According to the Centers fo...
(Date:12/1/2009)...eclines with age are more likely to engage in risk...isguided negative view of the aging process may ac...rage them to make the most of the present in antic... by Dr. John Garry and Dr. Maria Lohan from Queen,...hed online in Springer,s Journal of Happiness Stu...
(Date:12/1/2009)...cademic achievement, study finds , , TUE...cular system in young adulthood may boost brainpow...ll success later in life, new research suggests. ,... should know) the benefits of exercise and its imp... appearing in this week,s online issue of the Pro...
(Date:12/1/2009)..., Dec. 1 The first nutrition bar c...claimed for its potential to forestall the ravages...Photo: http://www.newscom.com/cgi-bin/prnh/200912.../cgi-bin/prnh/20091111/NY08935LOGO ) ,, The ap...nc. of Rancho Santa Fe, Calif. contains as much re...
(Date:12/1/2009)...RNewswire/ -- , - At ECPA,s Food Supply F...and Modes of Agriculture Will Require Science-Base...f Scientific Adviser to the UK government,asserte...science and have a,sound evidence basis. "Having a...to look at all stages of policy development has re...
Breaking Medicine News(10 mins):Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Binge drinking youths find getting old a drag 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3Health News:First Resveratrol Nutrition Bar Hits the Market 2Health News:Food Security to be the Top Issue for EU's Science Chief 2[0] Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory[0] Binge drinking youths find getting old a drag[0] Exercise May Lead to a Smarter, More Successful You[1] First Resveratrol Nutrition Bar Hits the Market[0] Food Security to be the Top Issue for EU's Science Chief
...s were found crawling on the surgical ward floor i...tly moved out of the ward at Dr Gray's Hospital in... dead bird on the ward’s roof was responsible for ... NHS Grampian spokesman said: "There was no health...
...study in the latest issue of the New England Journ...eart attack survivors. However more research is ne...udies looked at the effect of stem cells given to ...epair the main pumping chamber of the heart, but d...
...e committee on Wednesday passed a bill that will i...esentatives from the South and rural states said t...AIDS epidemic has changed the way it is spreading....n of the House Energy and Commerce Committee. "I d...
...nt study has revealed that vitamin shots may be be... in multiple sclerosis patients.//
Presently ...c progressive phase of MS, when serious disability...ng them a type of vitamin B3 known as nicotinamide...
...ne may help reduce Alzheimer's disease, says a stu...not yet tested if the findings apply to people.// ...Mount Sinai School of Medicine studied female mice...ion of science magazine WebMD.
The researche...
...in-one lotion that serves the basic purpose of a s...cancer has kindled the interests of researchers//,...have found a method to rectify a key pathway that ...he Melanoma Program at the Dana-Farber Cancer Inst...
Other Medicine News:Health News:Vitamin Shots to Combat MS Pain 2(Date:12/1/2009)... Dec. 1 CEL-SCI Corporat...any and a developer of vaccines and therapeutics f...ases, announced today that it has retained the ser...zation (CRO) to run CEL-SCI,s upcoming Phase III c...ncer with the Company,s lead product candidate, Mu...
(Date:12/1/2009)...N.J., Dec. 1 MedQuist ...ology-enabled clinical documentation services, tod...rimordial Design, Inc. has been integrated with Sp...ch recognition system. The solution is being demon...ca (RSNA) convention November 29 through December ...
(Date:12/1/2009)... TAI,AN, China, Dec. 1 /PRNewswire-Asia-FirstCall/...ard: CBPO) (Nasdaq: CBPO ) ("China Biologic," or,...opharmaceutical companies in,China, today announce...ts,common stock on the NASDAQ Global Market. ,,...rading on the NASDAQ on,Wednesday, December 2, 200...
Breaking Medicine Technology:CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2China Biologic Products Approved to List on NASDAQ 2China Biologic Products Approved to List on NASDAQ 3Shamir Optical Industry Ltd to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 53823 1Shamir Optical Industry Ltd to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 53823 2Sunrise Reports Financial Results for Second Quarter 2009 53821 1Sunrise Reports Financial Results for Second Quarter 2009 53821 2Sunrise Reports Financial Results for Second Quarter 2009 53821 3Sunrise Reports Financial Results for Second Quarter 2009 53821 4Sunrise Reports Financial Results for Second Quarter 2009 53821 5Sunrise Reports Financial Results for Second Quarter 2009 53821 6Sunrise Reports Financial Results for Second Quarter 2009 53821 7Sunrise Reports Financial Results for Second Quarter 2009 53821 8Sunrise Reports Financial Results for Second Quarter 2009 53821 9Sunrise Reports Financial Results for Second Quarter 2009 53821 10Sunrise Reports Financial Results for Second Quarter 2009 53821 11Sunrise Reports Financial Results for Second Quarter 2009 53821 12Sunrise Reports Financial Results for Second Quarter 2009 53821 13Sunrise Reports Financial Results for Second Quarter 2009 53821 14Sunrise Reports Financial Results for Second Quarter 2009 53821 15Sunrise Reports Financial Results for Second Quarter 2009 53821 16Sunrise Reports Financial Results for Second Quarter 2009 53821 17Sunrise Reports Financial Results for Second Quarter 2009 53821 18Sunrise Reports Financial Results for Second Quarter 2009 53821 19Sunrise Reports Financial Results for Second Quarter 2009 53821 20Ben Shappley Joins Amedicas Leadership Team 53817 1Ben Shappley Joins Amedicas Leadership Team 53817 2...day announced,its EXCOR(R) Pediatric ventricular a...oval for the ongoing IDE clinical trial in the Uni...istration (FDA) has fully,approved the Investigati...07, the FDA had granted conditional approval for t...centres with 10 patients, while the,company addres...
...imited (ASX:,CYT) will present data on its JAK2 in...gs this month., Dr Emmanuelle Fantino, Head of Bi...Targeted JAK2 Inhibitors for Myeloproliferative Di... Society of Australia and New,Zealand, in Perth, A...opher Burns, Cytopia,s Research Director, will pre...
Other Medicine Technology:Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 2Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 3Cytopia Scientific Presentations on JAK2 Inhibitor Program 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |